Joint API inspection pilot proves successful

pharmafile | August 17, 2011 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates 

Over recent years compliance with GMP in the manufacture of active substances (APIs) has been the subject of increasing regulatory interest. In May we reported that the consultation period for the European Medicines Agency’s (EMA’s) proposed template and associated Q&A document for GMP declarations in relation to active substances had ended and we advised applicants to plan accordingly. Of further note, the EMA and its international partners have also now published information about their positive experience in the pilot programmes which are part of the international collaboration concerning GMP inspections of active substance manufacturers. If you have any questions about GMP requirements or require a mock audit, we have a highly experienced team of GMP advisors and auditors. Contact us to discuss your requirements; email enquiries@wainwrightassociates.co.uk or telephone +44 (0)1628 530554 For more information visit www.wainwrightassociates.co.uk

Related Content

Submission of labels and leaflets in the UK

The MHRA has announced procedural changes concerning the requirement to submit full-colour mock-ups of labels …

On-going Medicine evaluation Information to be published by European Medicines Agency

Following the recommendations on transparency published by the European Heads of Medicines Agencies (HMA) and …

MHRA Inspections of CROs

In accordance with the provisions of the new pharmacovigilance legislation, as per Directive 2010/84/EU, EU …

Latest content